Evidence map›Paper›PMID 36900181›Full record

ArticleCancers2023

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

Lisa Pleyer, Sonja Heibl, Christoph Tinchon, Sonia Vallet, Martin Schreder, Thomas Melchardt, Norbert Stute, Kim Tamara Föhrenbach Quiroz, Michael Leisch, Alexander Egle and 11 more

2 registry-linked trialsFull text read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01595295 completednot on this map

Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)

TypeobservationalSponsorArbeitsgemeinschaft medikamentoese TumortherapieRan2009 to 2021Enrolled1,500ConditionsChronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid LeukemiaArmsnon interventional
NCT04438889 recruitingnot on this map

Austrian Myeloid Registry

Typeobservational_patient_registrySponsorArbeitsgemeinschaft medikamentoese TumortherapieRan2020 to 2030Enrolled3,000ConditionsMyeloid DiseasesArmsNon-interventional
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  2. Quality of Life in CAR-T Cell Therapy.Hematology reports · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lisa PleyerAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Sonja HeiblAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Christoph TinchonAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Sonia ValletAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Martin SchrederAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.ORCID 0000-0002-1699-9715
Thomas MelchardtAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Norbert StuteAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Kim Tamara Föhrenbach QuirozSalzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.
Michael LeischAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Alexander EgleAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Lukas ScagnettiAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Dominik WolfAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Richard BeswickInternational Marketing, Swiss Business School, 8302 Zurich, Switzerland.
Manuel DrostAssign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.
Julian Larcher-SennAssign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.ORCID 0000-0003-3169-1900
Thomas GrochtdreisDepartment of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.ORCID 0000-0002-0176-7989
Marc VaisbandAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.
Jan HasenauerLife and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
Nadja ZaborskySalzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria.ORCID 0000-0002-9775-185X
Richard GreilAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.ORCID 0000-0002-4462-3694
Reinhard StauderAustrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria.ORCID 0000-0002-8993-9561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%,

Indexed as

acute myeloid leukaemiaAustrian Registry of Hypomethylating Agentsazacitidinechronic myelomonocytic leukaemiaEuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)health-related quality of life (HRQoL)mixed-effects linear modelsmyelodysplastic syndromespatient-reported outcome (PRO)prognosis

Identifiers

PMID36900181
PMCPMC10000211

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read47
identifiers read2
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.